Literature DB >> 21967359

Complications of the management of status epilepticus in the intensive care unit.

Erich Schmutzhard1, Bettina Pfausler.   

Abstract

Barbiturates and propofol are widely used to control status epilepticus. This review aims to discuss all possible adverse effects incurred by the administration of GABA-mediated anesthetic agents. Further on unconventional therapies such as ketamine, lidocaine, or anesthetic agents are discussed both with respect to efficacy and complications. The aim of this review is to raise awareness of complications incurred by therapeutic approaches to patients with status epilepticus in the intensive care unit. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21967359     DOI： 10.1111/j.1528-1167.2011.03233.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN： 0013-9580            Impact factor:   5.864


  7 in total

1.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

2.  Observed medical and surgical complications of prolonged barbiturate coma for refractory status epilepticus.

Authors:  Christopher R Newey; Dolora Wisco; Premkumar Nattanmai; Aarti Sarwal
Journal:  Ther Adv Drug Saf       Date:  2016-07-18

Review 3.  Status Epilepticus.

Authors:  Syndi Seinfeld; Howard P Goodkin; Shlomo Shinnar
Journal:  Cold Spring Harb Perspect Med       Date:  2016-03-01       Impact factor: 6.915

4.  Anticonvulsant and Neuroprotective Effects of Paeonol in Epileptic Rats.

Authors:  Dong-Hai Liu; Elvis Agbo; Shu-Hong Zhang; Jin-Ling Zhu
Journal:  Neurochem Res       Date:  2019-09-13       Impact factor: 3.996

Review 5.  Metabolic and Homeostatic Changes in Seizures and Acquired Epilepsy-Mitochondria, Calcium Dynamics and Reactive Oxygen Species.

Authors:  Stjepana Kovac; Albena T Dinkova Kostova; Alexander M Herrmann; Nico Melzer; Sven G Meuth; Ali Gorji
Journal:  Int J Mol Sci       Date:  2017-09-08       Impact factor: 5.923

6.  KETASER01 protocol: What went right and what went wrong.

Authors:  Anna Rosati; Manuela L'Erario; Roberto Bianchi; Sara Olivotto; Domenica Immacolata Battaglia; Francesca Darra; Paolo Biban; Annibale Biggeri; Dolores Catelan; Giacomo Danieli; Maria Cristina Mondardini; Duccio Maria Cordelli; Angela Amigoni; Elisabetta Cesaroni; Alessandra Conio; Paola Costa; Martina Lombardini; Rosanna Meleleo; Alessandra Pugi; Elena Eve Tornaboni; Marta Elena Santarone; Roberta Vittorini; Stefano Sartori; Carla Marini; Federico Vigevano; Massimo Mastrangelo; Silvia Maria Pulitanò; Francesca Izzo; Lucia Fusco
Journal:  Epilepsia Open       Date:  2022-07-25

7.  Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01).

Authors:  Anna Rosati; Lucrezia Ilvento; Manuela L'Erario; Salvatore De Masi; Annibale Biggeri; Giancarlo Fabbro; Roberto Bianchi; Francesca Stoppa; Lucia Fusco; Silvia Pulitanò; Domenica Battaglia; Andrea Pettenazzo; Stefano Sartori; Paolo Biban; Elena Fontana; Elisabetta Cesaroni; Donatella Mora; Paola Costa; Rosanna Meleleo; Roberta Vittorini; Alessandra Conio; Andrea Wolfler; Massimo Mastrangelo; Maria Cristina Mondardini; Emilio Franzoni; Kathleen S McGreevy; Lorena Di Simone; Alessandra Pugi; Lorenzo Mirabile; Federico Vigevano; Renzo Guerrini
Journal:  BMJ Open       Date:  2016-06-15       Impact factor: 2.692
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.